Oxford Asset Management’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Oxford Asset Management’s Portfolio PGNX Stock Details PGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-444,687	Closed	-$1.87M	–	2152
2018 Q4	$1.87M	Buy	+444,687	New	+$2.26M	0.05%	507
2017 Q2	–	Sell	-456,033	Closed	-$4.3M	–	1789
2017 Q1	$4.3M	Buy	456,033 +180,618	+66%	+$1.8M	0.1%	188
2016 Q4	$2.38M	Buy	+275,415	New	+$2.04M	0.08%	275
2015 Q4	–	Sell	-382,027	Closed	-$2.19M	–	991
2015 Q3	$2.19M	Sell	382,027 -781,581	-67%	-$6M	0.07%	276
2015 Q2	$8.68M	Buy	1,163,608 +558,564	+92%	+$3.38M	0.24%	97
2015 Q1	$3.62M	Sell	605,044 -498,804	-45%	-$3.14M	0.09%	247
2014 Q4	$8.35M	Buy	1,103,848 +1,006,591	+1,035%	+$6.02M	0.18%	103
2014 Q3	$511K	Buy	+97,257	New	+$485K	0.01%	549
2014 Q2	–	Sell	-101,275	Closed	-$414K	–	815
2014 Q1	$414K	Buy	+101,275	New	+$518K	0.01%	536
2013 Q4	–	Sell	-127,856	Closed	-$643K	–	835
2013 Q3	$643K	Buy	+127,856	New	+$694K	0.01%	629

Other funds holding PGNX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

CTA

Carillon Tower Advisers St. Petersburg, Florida $16.4B AUM 64.75% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Oxford Asset Management's PGNX Position: Q1 2019 in Review

Oxford Asset Management sold out of Progenics Pharmaceuticals Inc (PGNX) in Q1 2019, closing a stake of 444,687 shares — an estimated $1.87M sold.

Oxford Asset Management first reported a position in PGNX in Q3 2013 and held it in 10 quarters. The position peaked at $8.68M in Q2 2015. 148 funds tracked by Wall St. Rank hold PGNX as of Q1 2019.

Oxford Asset Management reported no remaining Progenics Pharmaceuticals Inc position as of Q1 2019 after selling out during the quarter.
Oxford Asset Management sold 444,687 Progenics Pharmaceuticals Inc shares in Q1 2019, an estimated $1.87M.
Oxford Asset Management first reported a position in Progenics Pharmaceuticals Inc in Q3 2013 and held it in 10 quarters.
Oxford Asset Management's Progenics Pharmaceuticals Inc position peaked at $8.68M in Q2 2015.
148 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q1 2019.

Based on Oxford Asset Management's 13F filing for Q1 2019, filed 15 May 2019.